Pharmacologic treatment of migraine. Comparison of guidelines

Canadian Family Physician

Volumn 51, Issue JUNE, 2005, Pages 838-843

  Schuurmans, A ^a,c   van Weel, C ^b  

^a Dutch Institute for the Effective Use of Medication DGV   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIEMETIC AGENT; ANTIMIGRAINE AGENT; BARBITURIC ACID DERIVATIVE; CAFFEINE; CHLORPROMAZINE; CORTICOSTEROID; DICLOFENAC; DIHYDROERGOTAMINE; ERGOT ALKALOID; ERGOTAMINE; IBUPROFEN; KETOROLAC; MEFENAMIC ACID; NAPROXEN; NARATRIPTAN; NEW DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; PARACETAMOL; PHENOTHIAZINE; PLACEBO; RIZATRIPTAN; SUMATRIPTAN; TOLFENAMIC ACID; ZOLMITRIPTAN;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HEADACHE; HUMAN; INTERNET; MEDICAL DECISION MAKING; MEDICAL INFORMATION; MEDLINE; METHODOLOGY; MIGRAINE; NAUSEA AND VOMITING; PRACTICE GUIDELINE; PUBLICATION; SIDE EFFECT; THORAX PAIN; TREATMENT PLANNING; VASOCONSTRICTION;

ANALGESICS, NON-NARCOTIC; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIEMETICS; ERGOTAMINES; HUMANS; MIGRAINE DISORDERS; PRACTICE GUIDELINES; SEROTONIN AGONISTS; SUMATRIPTAN;

EID: 21044448860     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Van Weel C, Knottnerus JA. Evidence-based interventions and comprehensive treatment. Lancet 1999;353:916-8.
2. Lanzi G, Balottin U, Zambrino CA, Cernibori A, Del Bene E, Gallai V, et al. Guidelines and recommendations for the treatment of migraine in paediatric and adolescent patients. Italian Society for the Study of Headache. Funct Neurol 1996;11:269-75.
3. Bartelink ME, Van Duijn NP, Knuistingh NA, Ongering JEP Oosterhuis WW, Post D, et al. NHG-Standard migraine. In: Geijer RM, Burgers JS, Van der Laan JR, Wiersma T, Rosmalen CFH, Thomas S, et al, editors. NHG-Standards for the general practitioner I. Utrecht, The Netherlands: Netherlands College of General Practitioners; 1999.
4. Quality-control committee of the Netherlands Society for Neurology. Guidelines for diagnostics and treatment of chronic migraine headache recurrence without neurological abnormalities. Utrecht, The Netherlands: Netherlands Society for Neurology; 1997.
5. Matchar DB, Young WB, Rosenberg JH, Pietrzak MP, Silberstein SD, Lipton RB. et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management of acute attacks. Saint Paul, Minn: American Academy of Neurology; 2000. Available at www.aan.com/professionals/practice/pdfs/gl0087.pdf. Accessed 2005 May 2.
6. Snow V, Weiss K, Wall EM, Mottur-Pilson C, American Academy of Family Physicians, American College of Physicians-American Society of Internal Medicine. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Intern Med 2002; 137:840-9.
7. Pryse-Phillips WE, Dodick DW, Edmeads JG, Gawel MJ, Nelson RF, Purdy RA, et al. Guidelines for the diagnosis and management of migraine in clinical practice. Canadian Headache Society. CMAJ 1997;156(9):1273-87.
8. Canadian Association of Emergency Physicians. Guidelines for the acute management of migraine headache. J Emerg Med 1999;17(1):137-44.
9. Diener HC, Brune K, Gerber WD, Gobel H, Pfaffenrath V. Behandlung der Migräneattacke und Migräneprofylaxe. Empfehlungen der Deutschen Migräneund Kopfschmerzgesellschaft. [Treatment of migraine attacks and migraine prophylaxis: recommendations of the German Migraine and Headache Society]. Med Monatsschr Pharm 1998;21(2):30-9.
10. Therapeutics Initiative: Treatment of acute migraine headaches. Ther Lett 1997;22:1-2.
11. The oral sumatriptan and aspirin plus metoclopramide comparative study group. A study to compare oral sumatriptan with oral aspirin plus metoclopramide in the acute treatment of migraine. Eur Neurol 1992;32:177-84.
12. Tfelt-Hansen P, Henry P, Mulder LJ, Scheldewaert RG, Schoenen J, Chazot G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995;346:923-6.
13. The multinational oral sumatriptan and cafergot comparative study group. A randomised, double-blind comparison of sumatriptan and cafergot in the acute treatment of migraine. Eur Neurol 1991;31:314-22.
14. Winner F, Ricalde O, Le Force B, Saper J, Margul B. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996;53:180-4.
15. Welch KMA. Drug therapy of migraine. N Engl J Med 1993;329:1476-83.
16. Silberstein SD, Young WB. Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus. Working Panel of the Headache and Facial Pain Section of the American Academy of Neurology. Neurology 1995;45(3 Pt 1):577-84.
17. Kangasniemi P, Kaaja R. Ketoprofen and ergotamine in acute migraine. J Intern Med 1992;231(5)551-4.
18. Myllylä VV, Havanka H, Herrala L, Kangasniemi P, Rautakorpi I, Turkka J. et al. Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: comparable effect in a double-blind, randomized, controlled, parallel-group study. Headache 1999;38(3):201-7.
19. Touchon J, Bertin L, Pilgrim AJ, Ashford E, Res A. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the treatment of acute migraine. Neurology 1996;53(2):180-4.
20. Kelly AM, Ardagh M, Curry C, D'Antonio J, Zebic S. Intravenous chlorpromazine versus intramuscular sumatriptan for acute migraine. J Accid Emerg Med 1997;14(4):209-11.
21. Callaham M, Raskin N. A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache 1986;26:168-71.
22. Dahlof C. Placebo controlled trials with ergotamine in the acute treatment of migraine. Cephalalgia 1993;13:166-71.
23. The Agree Collaboration. Appraisal of guidelines research and evaluation. London, Engl: The Agree Collaboration; 2004. Available at: www.agreecollaboration.org. Accessed 2005 April 20.
24. Matchar DB, McCrory DC, Gray RN. Toward evidence-based management of migraine [editorial]. JAMA 2000;284:2640-1.
25. Lipton RB, Stewart WF, Stone AM, Lainez MI, Sawyer JP. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: a randomized trial. JAMA 2000;284:2599-605.
26. Evans KW, Boan JA, Evans JL, Shuaib A. Economic evaluation of oral sumatriptan compared with oral caffeine/ergotamine for migraine. Pharmacoeconomics 1997;12(5):565-77.
27. Williams P, Dowson AJ, Rapoport AM, Sawyer J. The cost effectiveness of stratified care in the management of migraine. Pharmacoeconomics 2001;19(8):819-29.
28. Goadsby PJ, Lipton RB, Ferrari MD. Migraine: current understanding and treatment. N Engl J Med 2002;346(4):257-70.
29. (B11) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358:1668-75.
30. McCrory DC, Gray RN. Oral sumatriptan for acute migraine. Cochrane Database Syst Rev 2003;(3): CD002915.
31. Smith LA, Oldman AD, McQuay HJ, Moore RA. Eletriptan for acute migraine. Cochrane Database Syst Rev 2001;(3):CD003224.
32. Oldman AD, Smith LA, McQuay HJ, Moore RA. Rizatriptan for acute migraine. Cochrane Database Syst Rev 2001;(3):CD003221.
33. The Diclofenac-K/Sumatriptan Migraine Study Group. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. Cephalagia 1999;19(4):232-40.
34. Freitag FG, Cady R, Diserio F, Elkind A, Gallagher RM, Goldstein J, et al. Comparative study of a combination of isometheptene mucate, dichloralphenazone with acetaminophen and sumatriptan succinate in the treatment of migraine. Headache 2001;41:391-8.